CoChat

OCULAR ADVERSE EVENTS ASSOCIATED WITH MEK INHIBITORS

Méndez-Martínez, Silvia, Calvo, Pilar, Ruiz-Moreno, Oscar, Pardiñas Barón, Nieves, Leciñena Bueno, Jesús, Gil Ruiz, María del Rocío, Pablo, Luis · 2019 · Retina

The DOI matches its Crossref record; 112 of the 112 references it cites were found in a registry or an index.

Abstract

Purpose: Mitogen-activates protein kinase (MAPK) inhibitors, particularly MEK inhibitors, have shifted the treatment paradigm for metastatic BRAF-mutant cutaneous melanoma; however, oncologists, ophthalmologists, and patients have noticed different toxicities of variable importance. This review aims to provide an update of the ocular adverse events (OAEs), especially retinal toxicity, associated with the use of MEK inhibitors. Methods: We conducted a scientific literature search using the PubMed database up to July 2018 with the terms “MEK inhibitors” with a “review” filter and “MEK inhibitors” with a “clinical trials” filter. Phase I–III experimental studies and reviews were selected. Current principles and techniques for diagnosing and managing MEK inhibitor retinopathy and other OAEs are discussed. Results: In patients treated with MEK inhibitors, including asymptomatic patients, OAEs occur with an incidence of up to 90%. Mild to severe ophthalmic toxicities are described, including visual disturbances, a 2-line decrease in Snellen visual acuity, dry eye symptoms, ocular adnexal abnormalities, visual field defects, panuveitis, and retinal toxicities, such as different degrees of MEK-associated retinopathy, vascular injury, and retinal vein occlusion. Conclusion: MEK inhibitors can lead to different degrees of retinal, uveal, and adnexal OAE, causing visual disturbances or discomfort. One of the most relevant OAE of MEK therapy is MEK inhibitor–associated retinopathy (MEKAR), which is usually mild, self-limited, and may subside after continuous use of the drug for weeks or months, or discontinuation, thereby restoring the normal visual function of the retina, with some exceptions. Ocular adverse events are often associated with other systemic adverse effects that can modify the dosage of treatment, so the communication with the oncologist is fundamental.

Overview

Integrity signals

Registry

Crossref · 10.1097/iae.0000000000002451

Cites

112 of 112 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 112 references

Cited by

See all 124

Metadata

Authors
Méndez-Martínez, S., Calvo, P., Ruiz-Moreno, O., Pardiñas Barón, N., Leciñena Bueno, J., Gil Ruiz, M. D. R., & Pablo, L.
Affiliations
  • Universidad de Zaragoza (ES)
  • Department of Ophthalmology, Miguel Servet University Hospital, IIS-Aragon, Zaragoza, Spain; and
Corresponding author
  • Méndez-Martínez, Silvia
  • Calvo, Pilar
  • Pablo, Luis
Venue
Retina
Published
2019-08
Volume
39
Issue
8
Pages
1435-1450
ISSN
0275-004X (ISSN-L)
OpenAlex
W2912028213
Cited by
117
References
112
Citations by year
2026: 9 · 2025: 22 · 2024: 16 · 2023: 19 · 2022: 22 · 2021: 18 · 2020: 9 · 2019: 2
FWCI
2.36
Type
journal article
Language
en
Open access
closed
Locations
  • Retina (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Ophthalmology › Drug-Induced Ocular Toxicity
  • Health Sciences › Medicine › Ophthalmology › Ocular Oncology and Treatments
  • Health Sciences › Medicine › Dermatology › Chemotherapy-related skin toxicity
Keywords
MEK inhibitors, ocular adverse effects, retinal toxicity, BRAF-mutant melanoma, MAPK inhibitors, retinal vein occlusion, panuveitis, dry eye, visual disturbances, drug toxicity management
MeSH terms
Humans, Retinal Diseases, Mitogen-Activated Protein Kinase Kinases, Protein Kinase Inhibitors, Drug-Related Side Effects and Adverse Reactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: OCULAR ADVERSE EVENTS ASSOCIATED WITH MEK INHIBITORS. https://app.cochat.ai/papers/10.1097/iae.0000000000002451
The paper
Méndez-Martínez, S., Calvo, P., Ruiz-Moreno, O., Pardiñas Barón, N., Leciñena Bueno, J., Gil Ruiz, M. D. R., & Pablo, L. (2019). OCULAR ADVERSE EVENTS ASSOCIATED WITH MEK INHIBITORS. Retina. https://doi.org/10.1097/iae.0000000000002451

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.